Phase 1 Open Label, Multi-center Study to Assess the Safety, tolerability and Pharmacokinetics of Orally administered CUDC-907, an HDAC and PI3K Inhibitor in Subjects with Advanced/ Relapsed Solid Tumors

Investigator: Pamela Munster, MD
Sponsor: Curis, Inc.

Location(s): United States


This is a Phase I, open-label, multi-center trial designed to evaluate the safety, tolerability and pharmacokinetics of CUDC-907 administered orally to subjects with advanced/relapsed solid tumors.